Rockville-based Novavax falls short of expectations 

Novavax Inc., of Rockville, which is developing vaccines to treat viral infections, reported a fourth-quarter net loss of $8 million, or 6 cents per diluted share, versus a net loss of $3.7 million, or 3 cents per share, in the prior-year period.